BioSpace News Archive

AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in the targeted patients.

Xeris Biopharma Holdings, Inc. today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP).

Immunocore Holdings Plc today announced that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference.

Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

Senti Biosciences, Inc. will host an Investor Event on December 11 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Replimune Group, Inc. today announced that members of its management team will present in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, December 1, 2022 at 1:00 PM ET.

Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference taking place at the Lotte New York Palace in New York.

Seelos Therapeutics, Inc. today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET.

Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 4:20 p.m. Eastern Time.

A novel approach to the treatment of opioid use disorder called Dual-Brain Psychology (DBP) has received a Phase II grant for continued research after publication showing promising results in a Phase 1 trial of 40 participants with opioid use disorder over the course of 4 weeks with an average decrease in opioid cravings of 71%.